30
Participants
Start Date
October 31, 2007
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
NB32
All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
Ancillary therapy
During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
Pharmacology Research Institute, Los Alamitos
Pharmacology Research Institute, Encino
Pharmacology Research Institute, Newport Beach
Lead Sponsor
Orexigen Therapeutics, Inc
INDUSTRY